Performance of Amino Acid Positons Emission Tomography in Brain Metastases
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: PET exam analysis.
- Who it may be relevant to
- Registry conditions: PET-CT. Basic parameters: 18 years — 90 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Static and Dynamic Performance of Amino Acid Positons Emission Tomography (PET) for Differentiating Radiation Necrosis From Tumor Progression in Irradiated Brain Metastases (DYNAMET)
Overview
Differentiating radiation necrosis from tumor progression in patients with brain metastases has a major therapeutic and prognostic implications
Detailed description
Differentiating radiation necrosis from tumor progression in patients with brain metastases treated with radiotherapy is a major challenge in post-treatment management, as the therapeutic and prognostic implications differ substantially depending on whether the lesion represents radiation necrosis (surveillance, anti-angiogenic therapy) or tumor progression (re-initiation of local or systemic treatment).
In addition to brain MRI, amino acid PET imaging, including both static and dynamic acquisitions, is a key diagnostic tool for this purpose.
However, the added value of dynamic acquisitions remains uncertain, and the available evidence is limited to small patient series.
Interventions
- Diagnostic test PET exam analysis
static and dynamic analyses
Primary outcome measures
- To compare the diagnostic performance amino acid PET imaging [Time frame: Day 1]
Secondary outcome measures (1)
- To evaluate the potential impact of immunotherapy administered before or during PET imaging [Time frame: 2 weeks]
Eligibility criteria
Inclusion criteria
- Patients who received a PET amino acid for differentiating radiation necrosis from progression of irradiated brain metastases,
Exclusion criteria
- Patients who refused the using of their data
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Other
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07676448 · 2026PI251